Severity of Disease and Clinical Outcomes in Patients With Hospital-Acquired Pneumonia Due to Methicillin-Resistant Staphylococcus aureus Strains Not Influenced by the Presence of the Panton-Valentine Leukocidin Gene
Author(s) -
Paula Peyrani,
Marty Allen,
Timothy L. Wiemken,
Nadia Z. Haque,
Marcus Zervos,
Kimbal D. Ford,
Ernesto G. Scerpella,
Julie E. Mangino,
Daniel H. Kett,
Julio A. Ramírez
Publication year - 2011
Publication title -
clinical infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1093/cid/cir541
Subject(s) - medicine , panton–valentine leukocidin , leukocidin , methicillin resistant staphylococcus aureus , pneumonia , staphylococcus aureus , antibiotics , community acquired pneumonia , microbiology and biotechnology , biology , bacteria , genetics
Patients with community-acquired pneumonia (CAP) infected with methicillin-resistant Staphylococcus aureus (MRSA) strains carrying the Panton-Valentine leukocidin (PVL) gene have severe clinical presentation and poor clinical outcomes. Antibiotics that suppress toxin production have been suggested for the management of these patients. The objective of this study was to compare the severity of disease and clinical outcomes of patients with hospital-acquired pneumonia/ventilator-associated pneumonia (HAP/VAP) infected with MRSA carrying the PVL gene with those patients infected with MRSA strains that do not carry the PVL gene.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom